SCHEMBL9980439

SCHEMBL9980439

CCOC(=O)Cn1cc(C(F)(F)F)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
JAK1 P23458 4/20 0.43
JAK2 O60674 4/20 0.43
PPARG P37231 2/20 0.43
TRPM2 O94759 1/20 0.42
GRIN1 Q05586 2/20 0.42
GRIN2B Q13224 2/20 0.42
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
HPGD P15428 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
GAA P10253 2/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
TYK2 P29597 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12997514 0.88 CYP2C9 (0.47) JAK1JAK2GSK3AGSK3BCYP2C9
SCHEMBL25039084 0.83 JAK1 (0.42) JAK1JAK2GSK3AGSK3BCYP2C9
SCHEMBL13172345 0.82 KDM4E (0.39) ALDH1A1
SCHEMBL12124191 0.81 ALPI (0.49) JAK1JAK2GSK3AGSK3BSMN1; SMN2
SCHEMBL29427323 0.79 GABRD (0.32) PPARG
SCHEMBL30595466 0.78 ACHE (0.42) POLBL3MBTL1HPGDCYP1A2CYP2C9
SCHEMBL12968057 0.78 GSK3A (0.44) JAK1JAK2GSK3AGSK3BSMN1; SMN2
SCHEMBL18623452 0.78 GSK3A (0.44) JAK1JAK2GSK3AGSK3BSMN1; SMN2
SCHEMBL14125781 0.78 GSK3A (0.44) JAK1JAK2GSK3AGSK3BSMN1; SMN2
SCHEMBL14149257 0.78 SMN1; SMN2 (0.44) JAK1JAK2GSK3AGSK3BSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091048-A1 GIP RECEPTOR AGONIST COMPOUNDS LILLY CO ELI (US) 2026-04-02 US disclosed
WO-2016051193-A1 COMPOUNDS USEFUL AS CSF1 MODULATORS REDX PHARMA PLC (GB) 2016-04-07 WO disclosed
WO-2016051193-A1 COMPOUNDS USEFUL AS CSF1 MODULATORS REDX PHARMA PLC (GB) 2016-04-07 WO disclosed
WO-2011150201-A2 AZOLYL AMIDE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2011-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091048-A1 GIP RECEPTOR AGONIST COMPOUNDS GIPR, GLP1R, GPR119 POLB 4745/4885L3MBTL1 3664/4885JAK1 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.